Thioredoxin Reductase

亜型選択性的な製品

Thioredoxin Reductase製品

  • All (3)
  • Thioredoxin Reductase阻害剤 (3)
  • 新製品
製品コード 製品名称 製品説明 文献中Selleckの製品使用例 お客様のフィードバック
S8068 Chaetocin Chaetocin, a natural product from Chaetomium species, is a histone methyltransferase inhibitor with IC50 of 0.8 μM, 2.5 μM and 3 μM for dSU(VAR)3-9, mouse G9a and Neurospora crassa DIM5, respectively. Chaetocin is an anticancer agent and inhibitor of thioredoxin reductase (TrxR).
Cancer Cell, 2023, 41(6):1118-1133.e12
Mol Ther, 2023, 10.1016/j.ymthe.2023.11.012
Clin Cancer Res, 2023, 29(1):271-278
S4307 Auranofin Auranofin (SKF-39162) is an inhibitor of thioredoxin reductase (TrxR) with IC50 of 88 nM for purified H. pylori TrxR in cell-free assay. Auranofin has anti-cancer activity and can completely inhibit bacterial growth at 1.2 μM. Auranofin is an FDA-approved gold-containing compound used for the treatment of rheumatoid arthritis.
Adv Healthc Mater, 2023, e2300591.
Theranostics, 2022, 12(12):5451-5469
Oncotarget, 2018,
S0267 TRi-1 TRi-1 (HUN20688, TXNRD1 inhibitor 1) is a potent, specific and irreversible cytosolic thioredoxin reductase 1 (TXNRD1) inhibitor with IC50 of 12 nM. TRi-1 exhibits anti-cancer activity while having little mitochondrial toxicity.
Int J Mol Sci, 2023, 24(15)12460
Oxid Med Cell Longev, 2022, 2022:7067623
S8068 Chaetocin Chaetocin, a natural product from Chaetomium species, is a histone methyltransferase inhibitor with IC50 of 0.8 μM, 2.5 μM and 3 μM for dSU(VAR)3-9, mouse G9a and Neurospora crassa DIM5, respectively. Chaetocin is an anticancer agent and inhibitor of thioredoxin reductase (TrxR).
Cancer Cell, 2023, 41(6):1118-1133.e12
Mol Ther, 2023, 10.1016/j.ymthe.2023.11.012
Clin Cancer Res, 2023, 29(1):271-278
S4307 Auranofin Auranofin (SKF-39162) is an inhibitor of thioredoxin reductase (TrxR) with IC50 of 88 nM for purified H. pylori TrxR in cell-free assay. Auranofin has anti-cancer activity and can completely inhibit bacterial growth at 1.2 μM. Auranofin is an FDA-approved gold-containing compound used for the treatment of rheumatoid arthritis.
Adv Healthc Mater, 2023, e2300591.
Theranostics, 2022, 12(12):5451-5469
Oncotarget, 2018,
S0267 TRi-1 TRi-1 (HUN20688, TXNRD1 inhibitor 1) is a potent, specific and irreversible cytosolic thioredoxin reductase 1 (TXNRD1) inhibitor with IC50 of 12 nM. TRi-1 exhibits anti-cancer activity while having little mitochondrial toxicity.
Int J Mol Sci, 2023, 24(15)12460
Oxid Med Cell Longev, 2022, 2022:7067623

Thioredoxin Reductase阻害剤の選択性比較

Tags: Thioredoxin Reductase inhibitor|Thioredoxin Reductase agonist|Thioredoxin Reductase activator|Thioredoxin Reductase inducer|Thioredoxin Reductase antagonist|Thioredoxin Reductase signaling pathway|Thioredoxin Reductase assay kit